Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Total Liabilities (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Total Liabilities for 6 consecutive years, with $53.2 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 11.88% to $53.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $53.2 million through Dec 2025, down 11.88% year-over-year, with the annual reading at $53.2 million for FY2025, 11.88% down from the prior year.
  • Total Liabilities for Q4 2025 was $53.2 million at Caribou Biosciences, roughly flat from $53.1 million in the prior quarter.
  • The five-year high for Total Liabilities was $80.2 million in Q2 2023, with the low at $35.7 million in Q1 2021.
  • Average Total Liabilities over 5 years is $61.9 million, with a median of $61.4 million recorded in 2024.
  • The sharpest move saw Total Liabilities surged 1599.48% in 2021, then fell 22.09% in 2024.
  • Over 5 years, Total Liabilities stood at $54.5 million in 2021, then skyrocketed by 33.67% to $72.9 million in 2022, then decreased by 12.46% to $63.8 million in 2023, then decreased by 5.4% to $60.4 million in 2024, then decreased by 11.88% to $53.2 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $53.2 million, $53.1 million, and $54.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.